Press release
Endometriosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma, Spago Nanomedical, Iqvia Pty, Nanjing Chia-tai Tianqing Pharm
To Know in detail about the Endometriosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endometriosis Market Forecast
https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Endometriosis Market Report:
• The Endometriosis market size was valued ~USD 2,300 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In October 2024, Lisata Therapeutics, Inc. has entered into a sponsored research agreement with the University of Cincinnati to study its innovative cyclic peptide candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor) using a preclinical animal model for endometriosis treatment.
• In October 2024, Hope Medicine Inc. reported positive interim results from its global Phase II trial evaluating HMI-115, a monoclonal antibody targeting the prolactin receptor, for treating moderate to severe endometriosis-associated pain. The randomized, multicenter, double-blind, placebo-controlled study assesses the safety and efficacy of HMI-115 over a 12-week treatment period. As a first-in-class therapy for endometriosis, HMI-115 has also received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA).
• In May 2024, Neurocrine Biosciences, Inc. announced the initiation of its Phase I first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions.
• In May 2024, TiumBio Co., Ltd., dedicated to developing innovative treatments for rare and incurable diseases, has reported positive topline results from its Phase 2a clinical trial of Merigolix. This oral gonadotropin-releasing hormone (GnRH) receptor antagonist is being evaluated for its effectiveness in managing moderate to severe endometriosis-associated pain.
• Among the total endometriosis market size across the 7MM, the United States held the largest share, reaching approximately USD 1,400 million in 2023.
• In 2023, the UK held the largest market share at approximately 20% within the EU4 and UK region, while Spain had the smallest share.
• In 2023, there were approximately 10.8 million diagnosed prevalent cases of endometriosis across the 7MM, with the highest number reported in the United States.
• Endometriosis is most prevalent among females aged 18-29, accounting for approximately 40% of all cases in the 7MM.
• In 2023, the total number of treated endometriosis cases was approximately 2.9 million in the US, followed by the UK and France.
• Key Endometriosis Companies: AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others
• Key Endometriosis Therapies: ORILISSA (elagolix), MYFEMBREE (relugolix, estradiol, and norethindrone acetate), ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 μg, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, and others
• As per the findings of Yoshino et al. (2022), around 2.6 million women in Japan are impacted by endometriosis.
• The Endometriosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endometriosis pipeline products will significantly revolutionize the Endometriosis market dynamics.
Endometriosis Overview
Endometriosis is a medical condition characterized by the presence of endometrial-like tissue outside the uterus, most commonly on the ovaries, fallopian tubes, and tissues lining the pelvis. This tissue responds to the hormonal changes of the menstrual cycle, leading to inflammation, pain, and the formation of scar tissue known as adhesions.
Get a Free sample for the Endometriosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Endometriosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Endometriosis Epidemiology Segmentation:
The Endometriosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Endometriosis
• Prevalent Cases of Endometriosis by severity
• Gender-specific Prevalence of Endometriosis
• Diagnosed Cases of Episodic and Chronic Endometriosis
Download the report to understand which factors are driving Endometriosis epidemiology trends @ Endometriosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Endometriosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometriosis market or expected to get launched during the study period. The analysis covers Endometriosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Endometriosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Endometriosis Therapies and Key Companies
• ORILISSA (elagolix): AbbVie
• MYFEMBREE (relugolix, estradiol, and norethindrone acetate): Myovant/Pfizer
• ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
• Linzagolix (OBE2109): ObsEva/Kissei Pharmaceutical
• Leuprolide Oral Tablet: Enteris BioPharma Inc.
• SN132D: Spago Nanomedical AB
• OG-6219: Iqvia Pty Ltd
• Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical
• Relugolix: Myovant Sciences GmbH
• HMI-115: Hope Medicine (Nanjing) Co., Ltd
• Quinagolide 1080 μg: Ferring Pharmaceuticals
• OBE2109: ObsEva
• SASHR7280: Jiangsu HengRui Medicine
• Estradiol/Norethindrone Acetate: AbbVie
• TAK-385: ASKA Pharmaceutical Co., Ltd.
• NBI-56418 (GnRH antagonist): Abbott
• KLH-2109: Kissei Pharmaceutical Co., Ltd.
• Dienogest (Visanne, BAY86-5258): Bayer
• ERB-041: Pfizer
Discover more about therapies set to grab major Endometriosis market share @ Endometriosis Treatment Landscape
https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Endometriosis Market Strengths
• The rising prevalence of endometriosis is the primary strength of its global market, leading to more focus by pharmaceutical firms
• At national and international levels, government and key market players actively invest in research and development and increase funds, further catering to market growth.
Endometriosis Market Opportunities
• Incumbents are paired with healthcare providers to raise awareness in the field of endometriosis at the physician and patient levels
• New diagnostic tools and techniques or methods can be explored for the early detection of endometriosis in the affected patient pool
Scope of the Endometriosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Endometriosis Companies: AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others
• Key Endometriosis Therapies: ORILISSA (elagolix), MYFEMBREE (relugolix, estradiol, and norethindrone acetate), ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109) , Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 μg, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, and others
• Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies
• Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Endometriosis Unmet Needs, KOL's views, Analyst's views, Endometriosis Market Access and Reimbursement
To know more about Endometriosis companies working in the treatment market, visit @ Endometriosis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Endometriosis Market Report Introduction
2. Executive Summary for Endometriosis
3. SWOT analysis of Endometriosis
4. Endometriosis Patient Share (%) Overview at a Glance
5. Endometriosis Market Overview at a Glance
6. Endometriosis Disease Background and Overview
7. Endometriosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Endometriosis
9. Endometriosis Current Treatment and Medical Practices
10. Endometriosis Unmet Needs
11. Endometriosis Emerging Therapies
12. Endometriosis Market Outlook
13. Country-Wise Endometriosis Market Analysis (2020-2034)
14. Endometriosis Market Access and Reimbursement of Therapies
15. Endometriosis Market Drivers
16. Endometriosis Market Barriers
17. Endometriosis Appendix
18. Endometriosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Endometriosis Epidemiology https://www.delveinsight.com/report-store/endometriosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Endometriosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Endometriosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports Offered By DelveInsight:
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
• Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometriosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma, Spago Nanomedical, Iqvia Pty, Nanjing Chia-tai Tianqing Pharm here
News-ID: 3888800 • Views: …
More Releases from DelveInsight Business Research
Triple Negative Breast Cancer Market Forecast 2034 - FDA Approvals, Clinical Tri …
DelveInsight's "Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Triple Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Triple Negative Breast Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and…
Relapsed/Refractory Multiple Myeloma Clinical Trial Pipeline Expands as 55+ Comp …
DelveInsight's, "Relapsed/Refractory Multiple Myeloma Pipeline Insight, 2025" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Relapsed/Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight's report, "Relapsing Refractory Multiple Myeloma Pipeline Insight 2025,"…
PD-L1 Inhibitors Market Set for Robust Growth Across 7MM, Driven by Novel Immuno …
The global PD-L1 inhibitors market is poised for substantial growth over the next decade, reflecting the transformative impact of immunotherapy on cancer treatment. In 2023, the PD-L1 inhibitors market across the seven major markets (7MM) reached approximately USD 36 billion, with the United States accounting for the largest share.
According to DelveInsight's latest report, "PD-L1 Inhibitors Market Insight, Epidemiology and Market Forecast - 2034", the PD-L1 inhibitors market in the seven…
BCL-2 Inhibitors Market Poised for Transformative Growth Driven by Next-Generati …
(Albany, USA) - The BCL-2 inhibitors market is on the cusp of remarkable expansion over the next decade, propelled by increasing cancer incidence, growing awareness of apoptosis-targeting therapies, and the rapid evolution of clinical research in hematologic malignancies.
According to DelveInsight's latest market report, "B-Cell Leukemia/Lymphoma-2 (BCL-2) Inhibitors Market Size, Epidemiology, Competitive Landscape, and Market Forecast - 2034," the global market is expected to experience substantial growth across the United…
More Releases for Endometriosis
Endometriosis Pain Market Massive Growth opportunity Ahead
Introduction
Endometriosis is a chronic, estrogen-dependent condition in which endometrial-like tissue grows outside the uterus, leading to inflammation, scarring, and adhesions. One of its most debilitating symptoms is pelvic pain, often accompanied by painful periods, infertility, and fatigue. Globally, endometriosis affects an estimated 10% of women of reproductive age, making it a major public health concern.
Despite its prevalence, endometriosis pain has historically been underdiagnosed and undertreated. Patients often face diagnostic delays…
Elevated Ovarian Cancer Incidence Fuels Growth In The Endometriosis Market: A Ke …
The Endometriosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Endometriosis Market Size and Its Estimated Growth Rate?
In recent years, there has been a swift expansion in the market size of endometriosis. This market is projected to increase from $1.4 billion…
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare
EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to…
Emerging Endometriosis Market Trend 2025-2034: Innovative Medications Reshaping …
"How Is the Endometriosis Market Projected to Grow, and What Is Its Market Size?
The endometriosis market has seen rapid growth in recent years. It is expected to grow from $1.4 billion in 2024 to $1.55 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. The growth can be attributed to delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the support of patient advocacy groups.
The…
Endometriosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Endometriosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Endometriosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Endometriosis Market Size, Share, Insight, Treatment 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Endometriosis Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.01 billion In 2028 At A…
